Trials / Completed
CompletedNCT05891366
Single Ascending Dose Study of WAL0921 in Healthy Subjects
Safety, Pharmacokinetics, and Pharmacodynamics of a Single, Ascending Dose of WAL0921 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Walden Biosciences · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This is a randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of WAL0921 in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | WAL0921 | Investigational product WAL0921 |
| DRUG | Placebo | Placebo product |
Timeline
- Start date
- 2023-05-31
- Primary completion
- 2024-01-09
- Completion
- 2024-01-09
- First posted
- 2023-06-06
- Last updated
- 2024-04-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05891366. Inclusion in this directory is not an endorsement.